Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Campaign to celebrate World Mental Health Day theme "Mental Health in an Unequal World"
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
